Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas

Breast Cancer Research and Treatment

Volumn 116, Issue 3, 2009, Pages 449-460

  Wargon, Victoria ^a   Helguero, Luisa A ^a,b   Bolado, Julieta ^a   Rojas, Paola ^a   Novaro, Virginia ^a   Molinolo, Alfredo ^a,c   Lanari, Claudia ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Acquired hormone resistance; AKT; Antiprogestins; Breast cancer; De novo hormone resistance; ERK; Estrogen receptors; Hormone resistance; Metastasis; Progesterone receptor isoforms; Tumor regression

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; LONAPRISAN; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; PROTEIN KINASE B; TAMOXIFEN; HORMONE ANTAGONIST; ISOPROTEIN; PROGESTERONE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST CARCINOMA; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; FEMALE; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG RESISTANCE; EXPERIMENTAL NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PATHOLOGY; SURVIVAL RATE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HORMONE ANTAGONISTS; LYMPHATIC METASTASIS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MIFEPRISTONE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, PROGESTERONE; SURVIVAL RATE;

EID: 70349577376     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0150-y     Document Type: Article

References (55)

1. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura A et al (2005) Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer 12(Suppl 1):S61-S73. doi: 10.1677/erc.1.01018
2. Osborne CK, Schiff R (2003) Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 12:362-367. doi:10.1016/S0960-9776 (03)00137-1
3. Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A et al (2005) Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 12:721-747. doi:10.1677/erc.1.00857
4. Haslam SZ (1988) Progesterone effects on deoxyribonucleic acid synthesis in normal mouse mammary glands. Endocrinology 122:464-470
5. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA Jr et al (1995) Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 9:2266-2278. doi:10.1101/gad.9.18.2266
6. Montero GG, Vanzulli SI, Cerliani JP, Bottino MC, Bolado J, Vela J et al (2007) Association of estrogen receptor alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment. Breast Cancer Res 9:R22. doi:10.1186/bcr1660
7. Kordon EC, Molinolo AA, Pasqualini CD, Charreau EH, Pazos P, Dran G et al (1993) Progesterone induction of mammary carcinomas in BALB/c female mice. Correlation between progestin dependence and morphology. Breast Cancer Res Treat 28:29-39. doi:10.1007/BF00666353
8. Moore MR (2004) A rationale for inhibiting progesterone-related pathways to combat breast cancer. Curr Cancer Drug Targets 4:183-189. doi:10.2174/1568009043481515
9. Lanari C, Molinolo AA, Pasqualini CD (1986) Induction of mammary adenocarcinomas by medroxyprogesterone acetate in BALB/c female mice. Cancer Lett 33:215-223. doi:10.1016/0304-3835(86)90027-3
10. Lanari C, Molinolo A (2002) Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer. Breast Cancer Res 4:240-243. doi:10.1186/bcr539
11. Aldaz CM, Liao QY, LaBate M, Johnston DA (1996) Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. Carcinogenesis 17:2069-2072. doi:10.1093/carcin/17.9.2069
12. Women's Health Initiative (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321-333. doi:10.1001/jama.288.3.321
13. Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419-427. doi: 10.1016/S0140-6736(03)14596-5
14. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H et al (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9:1603-1614
15. Leo JC, Lin VC (2008) The activities of progesterone receptor isoform A and B are differentially modulated by their ligands in a gene-selective manner. Int J Cancer 122:230-243. doi:10.1002/ijc.23081
16. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB (2002) Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277:5209-5218. doi:10.1074/jbc.M110090200
17. Shyamala G, Yang X, Silberstein G, Barcellos-Hoff MH, Dale E (1998) Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary glands. Proc Natl Acad Sci USA 95:696-701. doi:10.1073/pnas.95.2.696
18. Shyamala G, Yang X, Cardiff RD, Dale E (2000) Impact of progesterone receptor on cell-fate decisions during mammary gland development. Proc Natl Acad Sci USA 97:3044-3049. doi: 10.1073/pnas.97.7.3044
19. Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM (2003) Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci USA 100:9744-9749. doi:10.1073/pnas.1732707100
20. Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB et al (2004) Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 10:2751-2760. doi:10.1158/1078-0432.CCR-03- 0141
21. Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J et al (2004) Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst 96:456-465
22. Macedo LF, Sabnis GJ, Goloubeva OG, Brodie A (2008) Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res 68:3516-3522. doi: 10.1158/0008-5472.CAN-07-6807
23. Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA (2007) Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 18: 1323-1328. doi:10.1093/annonc/mdm170
24. Boylan M, van den Berg HW, Lynch M (1998) The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen. Ann Oncol 9:205-211. doi:10.1023/A:1008241804078
25. Lin X, Yu Y, Zhao H, Zhang Y, Manela J, Tonetti DA (2006) Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model. Carcinogenesis 27:1538-1546. doi:10.1093/carcin/bgl002
26. Naundorf H, Fichtner I, Saul GJ, Haensch W, Buttner B (1993) Establishment and characteristics of two new human mammary carcinoma lines serially transplantable in nude mice. J Cancer Res Clin Oncol 119:652-656. doi:10.1007/BF01215983
27. Molinolo AA, Lanari C, Charreau EH, Sanjuan N, Pasqualini CD (1987) Mouse mammary tumors induced by medroxyprogesterone acetate: immunohistochemistry and hormonal receptors. J Natl Cancer Inst 79:1341-1350
28. Vanzulli SI, Soldati R, Meiss R, Colombo L, Molinolo AA, Lanari C (2005) Estrogen or antiprogestin treatment induces complete regression of pulmonary and axillary metastases in an experimental model of breast cancer progression. Carcinogenesis 26:1055-1063. doi:10.1093/carcin/bgi060
29. Simian M, Molinolo A, Lanari C (2006) Involvement of matrix metalloproteinase activity in hormone-induced mammary tumor regression. Am J Pathol 168:270-279. doi:10.2353/ajpath.2006. 050012
30. Fabris VT, Benavides F, Conti C, Merani S, Lanari C (2005) Cytogenetic findings, Trp53 mutations, and hormone responsiveness in a medroxyprogesterone acetate induced murine breast cancer model. Cancer Genet Cytogenet 161:130-139. doi: 10.1016/j.cancergencyto.2005.02.008
31. Institute of Laboratory Animal Resources CoLSNRC (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington, DC
32. Kordon EC, Guerra F, Molinolo AA, Charreau EH, Pasqualini CD, Pazos P et al (1994) Effect of sialoadenectomy on medroxyprogesterone-acetate-induced mammary carcinogenesis in BALB/c mice. Correlation between histology and epidermalgrowth- factor receptor content. Int J Cancer 59:196-203. doi: 10.1002/ijc.2910590210
33. Helguero LA, Viegas M, Asaithamby A, Shyamala G, Lanari C, Molinolo AA (2003) Progesterone receptor expression in medroxyprogesterone acetate-induced murine mammary carcinomas and response to endocrine treatment. Breast Cancer Res Treat 79:379-390. doi:10.1023/A:1024029826248
34. Vanzulli S, Efeyan A, Benavides F, Helguero L, Peters G, Shen J et al (2002) p21, p27 and p53 in estrogen and antiprogestininduced tumor regression of experimental mouse mammary ductal carcinomas. Carcinogenesis 23:749-757. doi:10.1093/carcin/23.5.749
35. Liu W, Bagaitkar J, Watabe K (2007) Roles of AKT signal in breast cancer. Front Biosci 12:4011-4019. doi:10.2741/2367
36. Montecchia MF, Lamb C, Molinolo AA, Luthy IA, Pazos P, Charreau E et al (1999) Progesterone receptor involvement in independent tumor growth in MPA-induced murine mammary adenocarcinomas. J Steroid Biochem Mol Biol 68:11-21. doi: 10.1016/S0960-0760(98)00166-6
37. Aupperlee MD, Smith KT, Kariagina A, Haslam SZ (2005) Progesterone receptor isoforms A and B: temporal and spatial differences in expression during murine mammary gland development. Endocrinology 146:3577-3588. doi:10.1210/en.2005-0346
38. Horwitz KB, Tung L, Takimoto GS (1996) Novel mechanisms of antiprogestin action. Acta Oncol 35:129-140. doi:10.3109/0284 1869609098493
39. Lamb CA, Helguero LA, Giulianelli S, Soldati R, Vanzulli SI, Molinolo A et al (2005) Antisense oligonucleotides targeting the progesterone receptor inhibit hormone-independent breast cancer growth in mice. Breast Cancer Res 7:R1111-R1121. doi:10.1186/bcr1345
40. Dran G, Luthy IA, Molinolo AA, Charreau EH, Pasqualini CD, Lanari C (1995) Effect of medroxyprogesterone acetate (MPA) and serum factors on cell proliferation in primary cultures of an MPA-induced mammary adenocarcinoma. Breast Cancer Res Treat 35:173-186. doi:10.1007/BF00668207
41. Arruvito L, Giulianelli S, Flores AC, Paladino N, Barboza M, Lanari C et al (2008) NK cells expressing a progesterone receptor are susceptible to progesterone-induced apoptosis. J Immunol 180:5746-5753
42. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK et al (1981) Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304:16-21
43. Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Ravdin RG, Talley RW, Potter NR (1977) Diethylstilbestrol recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA 237:2079-2085
44. Beex L, Pieters G, Smals A, Koenders A, Benraad T, Kloppenborg P (1981) Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rep 65:179-185
45. Lonning PE, Taylor PD, Anker G, Iddon J, Wie L, Jorgensen LM et al (2001) High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 67:111-116. doi:10.1023/A:101061 9225209
46. Conneely OM, Jericevic BM, Lydon JP (2003) Progesterone receptors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 8:205-214. doi:10.1023/A:1025952924864
47. Weigel RJ, deConinck EC (1993) Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma. Cancer Res 53:3472-3474
48. Ferguson AT, Lapidus RG, Davidson NE (1998) Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression. Oncogene 17:577-583. doi: 10.1038/sj.onc.1201961
49. Martin LA, Farmer I, Johnston SR, Ali S, Dowsett M (2005) Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr Relat Cancer 12(Suppl 1):S75-S84. doi:10.1677/erc.1.01023
50. Brodie A, Sabnis G, Jelovac D (2006) Aromatase and breast cancer. J Steroid Biochem Mol Biol 102:97-102. doi:10.1016/j. jsbmb.2006.09.002
51. Qiu M, Olsen A, Faivre E, Horwitz KB, Lange CA (2003) Mitogen activated protein kinase regulates nuclear association of human progesterone receptors. Mol Endocrinol 17:628-642. doi: 10.1210/me.2002-0378
52. Labriola L, Salatino M, Proietti CJ, Pecci A, Coso OA, Kornblihtt AR et al (2003) Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells. Mol Cell Biol 23:1095-1111. doi:10.1128/MCB.23.3.1095-1111.2003
53. Faivre EJ, Daniel AR, Hillard CJ, Lange CA (2008) Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol Endocrinol 22:823-837. doi:10.1210/me.2007-0437
54. Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S et al (2006) Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 13:137-144. doi: 10.2325/jbcs.13.137
55. Toker A, Yoeli-Lerner M (2006) Akt signaling and cancer: surviving but not moving on. Cancer Res 66:3963-3966. doi: 10.1158/0008-5472.CAN-06-0743